SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

HSBCs bearish assessment of CoreWeaves debt burden, financing costs and exposure to slower AI demand has fueled concern about the neocloud companys ability to fund growth. Traders are split between viewing the selloff as evidence of fundamental risk and buying the rebound while anticipating a short squeeze.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Middle East tensions and reported attacks on oil shipping and energy infrastructure have focused attention on crude supply-disruption risks, while speculation about US-Iran mediation has fueled sharp swings. Bulls point to potential supply constraints; bears argue that a deal or normalized shipping could unwind the risk premium and that the rally is overextended.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins rebound from recent lows has traders focused on whether it can clear nearby resistance and sustain a recovery. Bulls see breakout and short-squeeze potential, while skeptics call the move a false start and point to weak demand and broader macro risks.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

CEO Angelos Stergious 15th-anniversary LinkedIn post about the companys next chapter with GPS and SLS009 has fueled speculation about a potential buyout and imminent clinical news, though neither was confirmed. Discussion also centers on the REGAL Phase 3 trials final analysis, triggered at 80 deaths versus 78 last disclosed: bulls view the extended wait as potentially encouraging, while skeptics say the blinded trials timing cannot establish efficacy and question managements communication.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows is drawing attention as traders connect the stocks political-sentiment exposure to Trumps weakening approval and the approaching midterms, while also criticizing the companys limited revenue and crypto exposure. The conversation is broadly bearish, though some traders see the decline as setting up a short-term bounce.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is caught in a sharp neocloud and AI-infrastructure selloff as traders debate concerns about debt, funding costs, and whether projected AI demand will justify the sectors buildout. Bears expect further declines, while bulls call the stock oversold and point to managements financing comments and IRENs power and data-center assets as reasons for a rebound;

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

An intraday QQQ rebound was widely linked by traders to unconfirmed reports of a possible US-Iran deal and a pullback in oil prices. The community disputed the reports credibility and whether the move was sustainable or a bull trap, with elevated oil and tech-sector volatility adding to the uncertainty.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is drawing attention after a sharp semiconductor selloff and volatile rebound, as traders debate whether concerns about AI spending, debt and returns signal a deeper sector correction. Bulls point to ongoing chip demand and oversold conditions as reasons for a bounce, while bears warn that selling may continue.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Unconfirmed reports of a possible U.S.-Iran deal dominated discussion around SPYs sharp rally, with traders linking the reports and a drop in oil to improved risk appetite. Some chased the move as peace news; others questioned the reports credibility and called the rally a potential trap or short-lived pump.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces strong third-quarter results and raised 2026 outlook are being overshadowed by a share-price decline, with traders pointing to rising costs, weaker free cash flow and a loss in the insurance business. Bulls call the pullback unwarranted after the beat, while others focus on cost pressures and supply constraints.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm PR Newswire LOS ANGELES, June 8, 2026 LOS ANGELES, June 8, 2026 /PRNewswire...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grace Therapeutics, Inc. (Grace or the Company) (NASDAQ: GRCE) for violations of the securities laws.The investigation focuses on whether the Company issued false...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace...

GRCE Stock On Track For Worst Week In 5.5 Years —  What’s Driving The Selloff?

Equity

Earlier this week, the FDA refused to approve Grace Therapeutics’s experimental drug for the treatment of a severe form of acute brain injury.


GRCE Stock Plunges 45% After FDA Rejects Brain Injury Drug — Company Says Concerns Are Fixable

Grace Therapeutics was seeking FDA approval for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage. 


GRCE Stock In Spotlight Ahead Of FDA Verdict On Brain Bleed Drug This Week 

The FDA set a Prescription Drug User Fee Act target action date of April 23 to rule on GTx-104, a potential treatment for patients with aneurysmal subarachnoid hemorrhage.

Short Interest in Grace Therapeutics, Inc. (NASDAQ:GRCE) Grows By 300.8%

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling...

Grace Therapeutics, Inc. (NASDAQ:GRCE) Short Interest Update

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 27th, there was short interest totaling...

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the target of a significant growth in short interest during the month of February. As of February 13th, there was short interest totaling...

Grace Therapeutics (NASDAQ:GRCE) Announces Earnings Results

Grace Therapeutics (NASDAQ:GRCE - Get Free Report) posted its earnings results on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus...

Grace Therapeutics, Inc. engages in the development and commercialization of drug candidates for rare and orphan diseases. It focuses on utilizing proprietary technologies to improve the performance of currently marketed drugs. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.

Grace Therapeutics Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>Grace was seeking FDA approval for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage.</li><li>However, the FDA issued a letter to it on Thursday, citing issues in the Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections of its application.</li><li>Analysts from Craig-Hallum and TD Cowen slashed price targets on the stock on Friday following the FDA decision.</li></ul><p>Shares of Grace Therapeutics (GRCE) are on track for their worst week since Sept. 2020, after the U.S. Food and Drug Administration refused to approve its experimental drug for the treatment of a severe form of acute brain injury, sparking price target cuts.</p><p>Shares of the company are down 49% this week, if losses hold.</p><h2 class="st-heading-2">FDA Rejection</h2><p>Grace was seeking FDA approval for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage (aSAH), or bleeding over the surface of the brain in the space between the brain and the skull as a result of a ruptured brain aneurysm.</p><p>However, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/grce-stock-plunges-after-fda-rejects-brain-injury-drug-company-says-concerns-are-fixable/cZBQevVReTT">issued </a>a letter to it on Thursday, citing issues in the Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections of its application. The agency highlighted leachables data for product packaging, non-clinical product toxicology risk assessments, and product manufacturing deficiencies at the company’s contract manufacturing organization, it said.</p><h2 class="st-heading-2">Wall Street Weighs In</h2><p>Craig-Hallum lowered the firm's price target on Grace Therapeutics to $4 from $11 and kept a ‘Buy’ rating on the shares following the announcement. The firm believes Grace has enough runway to address the deficiencies highlighted by the FDA and an application resubmission, though shares are unlikely to move higher until further visibility is provided, it said.</p><p>TD Cowen analyst Stacy Ku also lowered the firm's price target on Grace Therapeutics to $8 from $12 and kept a ‘Buy’ rating on the shares. The firm noted that GTx-104's rejection is related to CMC, with no requests for additional clinical data. Management will seek a meeting with the FDA, which should clarify resubmission timelines, the analyst said. The firm assumes a roughly 12-month delay, with potential for faster resolution.</p><h2 class="st-heading-2">Grace Chimes In</h2><p>“We are confident in the robust data package supporting our NDA (application) submission, and that the CMC issues identified by the FDA can be successfully addressed in our resubmission,” CEO Prashant Kohli said on Thursday following the receipt of the FDA letter.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around GRCE stock stayed within ‘bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.</p><p>A Stocktwits user highlighted that the issues cited by the FDA are fixable and the stock will bounce back up.</p><p><stembedurl>https://www.stocktwits.com/h8ster/message/651317731</stembedurl></p><p>Another user dismissed the rejection and instead highlighted possible risks of dilution from capital raising initiatives.</p><p><stembedurl>https://www.stocktwits.com/Stockseeking/message/651266436</stembedurl></p><p><a href="https://stocktwits.com/symbol/GRCE">GRCE stock</a> is down 8% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cmps-on-track-for-best-week-ever-on-fda-push-for-psychedelics/cZBhaQDReck">CMPS On Track For Best Week Ever On FDA Push For Psychedelics</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

Earlier this week, the FDA refused to approve Grace Therapeutics’s experimental drug for the treatment of a severe form of acute brain injury.

Vanguard Total Stock Market ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$2.04
Prev Close	$1.88
Open	$1.96
Dividend Yield	0.00%
50-Day Moving Average	$2.11
Beta	1.11
Avg. Volume	146,974.85
PE Ratio	-1.59

52-Week High	$5.18
52-Week Low	$1.79
Market Capitalization	$39.55M
EPS (Annual)	-$0.472
Price to Book	0.63
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

GRCE Fundamentals